SimBioSys, a pioneering TechBio company leveraging Artificial Intelligence (AI), spatial biophysics, and data science to redefine precision medicine and combat cancer, proudly announces its role as one of the founding members of the CancerX initiative. CancerX, introduced by the White House Cancer Moonshot, is a collaborative effort between the Digital Medicine Society (DiMe) and Moffitt Cancer Center, aiming to accelerate innovation in the battle against cancer.

CancerX brings together DiMe's proficiency in assembling interdisciplinary teams for swift development of clinical-quality resources and Moffitt's leading experts in research and patient care. Their joint objective is to revolutionize cancer treatment, enhance access to top-tier care, and ultimately save lives. This initiative welcomes all professionals committed to collaborative work and sharing a vision of harnessing innovation's potential to shape a cancer-free future.

Dr. Anu Antony, Surgeon and Chief Medical Officer at SimBioSys, underscores the significance of this partnership, stating, "As a trusted TechBio company focused on precision medicine solutions using AI and data science to address the spatial biophysics challenges of tumor heterogeneity, I am proud of this impactful partnership with CancerX that serves to accelerate our scientific capabilities and enhance medical knowledge to serve patients. Our mission is to meaningfully and equitably empower clinicians and patients in the brave fight against cancer, mobilizing innovation with scientific integrity to tackle the real-world challenges facing the cancer community."

Smit Patel, Associate Program Director at DiMe, highlights the critical role of multi-stakeholder collaboration in utilizing digital innovation to combat cancer. Patel expresses enthusiasm about partnering with SimBioSys to achieve CancerX's ambitious goals, stating, "Through this impressive collaboration, we will establish best practices, build capacity, and demonstrate the impact of innovation on the life of every person on a cancer journey."

CancerX takes inspiration from successful approaches seen in established HHS InnovationX program accelerators like KidneyX and PandemicX. The initiative is set to build upon these models, with a focus on supporting startups to scale operations and emphasize health equity. The first demonstration project under CancerX is expected to be unveiled in April 2024.